All In Biotech

Drug Trial Radar · NCT05054140

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Apr 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

450

Planned (sponsor's estimate)

Start

Sep 30, 2021

Primary completion

Jan 7, 2025

Study completion Jan 7, 2025

Sponsor

Lead sponsor
Immunic AGIndustry
Sponsor type
Industry
First posted
Sep 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis - CALLIPER

Conditions

  • Multiple Sclerosis

Interventions

  • IMU-838Drug

    IMU-838 tablets

  • Placebo matching IMU-838Drug

    Placebo matching IMU-838 tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of IMU-838 versus placeboTime frame: 120 weeks

Locations

73 sites in 12 countries. Site status is shown where the registry gives one.

  • Dr. Sonia Kalirao

    Coral Springs, Florida

  • Collier Neurologic Specialists

    Naples, Florida

  • Prof. James Scott

    Ormond Beach, Florida

  • Shepherd Center

    Atlanta, Georgia

  • Consultants in Neurology, Ltd.

    Northbrook, Illinois

  • Dr. Daniel Becker

    Lutherville, Maryland

  • Dr. Mirela Cerghet

    Detroit, Michigan

  • University of New Mexico (UNM), MS Specialty Clinic

    Albuquerque, New Mexico

  • MHAT Pulse

    Blagoevgrad, Bulgaria

  • MHAT"Heart and Brain" EAD

    Burgas, Bulgaria

  • Dr. Maya Danovska

    Pleven, Bulgaria

  • Dr. Plamen Bozhinov

    Pleven, Bulgaria

  • UMHAT Pulmed

    Plovdiv, Bulgaria

  • Dr. Rositsa Krasteva

    Rousse, Bulgaria

  • Dr. Nikolay Georgiev

    Shumen, Bulgaria

  • MHAT Shumen

    Shumen, Bulgaria

  • Dr. Ivan Milanov

    Sofia, Bulgaria

  • MHAT Lyulin

    Sofia, Bulgaria

  • Dr. Rosen Ikonomov

    Sofia, Bulgaria

  • Dr. Penko Shotekov

    Sofia, Bulgaria

  • UMHAT Alexandrovska

    Sofia, Bulgaria

  • Dr. Kana Prinova

    Sofia, Bulgaria

  • Dr. Kosta Kostov

    Sofia, Bulgaria

  • MHAT Sveta Sofia

    Sofia, Bulgaria

  • UMHATSM N.I.Pirogov

    Sofia, Bulgaria

  • UMHAT Prof. Stoyan Kirkovich

    Stara Zagora, Bulgaria

  • Dr. Ara Kaprelyan

    Varna, Bulgaria

  • Montreal Neurological Inst.

    Montreal, Canada

  • The Ottawa Hospital Research Institute

    Ottawa, Canada

  • Fakultni nemocnice

    Hradec Králové, Czechia

  • Datamed GmbH

    Cologne, Germany

  • Klinik und Poliklinik für Neurologie, Universitätsklinikum Dresden

    Dresden, Germany

  • Neuro Centrum Science GmbH

    Erbach im Odenwald, Germany

  • Universitätsklinikum Hamburg Eppendorf

    Hamburg, Germany

  • Dr. Stanislav Groppa

    Chisinau, Moldova

  • Dr. Mihail Gavriliuc

    Chisinau, Moldova

  • Dr. Olesea Odainic

    Chisinau, Moldova

  • Dr. Eva Strijibis

    Amsterdam, Netherlands

  • Alrijne ziekenhuis

    Leiderdorp, Netherlands

  • Dr. Ana Doneva Skopje 1000

    Skopje, North Macedonia

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.